[
  {
    "ts": "2025-08-06T13:36:40+00:00",
    "headline": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
    "summary": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
    "url": "https://finance.yahoo.com/news/snap-downgraded-leidos-upgraded-wall-133640590.html",
    "source": "The Fly",
    "provider": "yfinance",
    "raw": {
      "id": "56d775ec-ed9a-3792-bb29-64101908a6b6",
      "content": {
        "id": "56d775ec-ed9a-3792-bb29-64101908a6b6",
        "contentType": "STORY",
        "title": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
        "description": "",
        "summary": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
        "pubDate": "2025-08-06T13:36:40Z",
        "displayTime": "2025-08-06T13:36:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec",
          "originalWidth": 1200,
          "originalHeight": 628,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YHTvjvqtNAYBPYViMXYCow--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec.cf.webp",
              "width": 1200,
              "height": 628,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J3gfZRz3Jb2im4_aLYVn4g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Fly",
          "url": "https://thefly.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/snap-downgraded-leidos-upgraded-wall-133640590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/snap-downgraded-leidos-upgraded-wall-133640590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MNDY"
            },
            {
              "symbol": "CACI"
            },
            {
              "symbol": "SEAT"
            },
            {
              "symbol": "SEATW"
            },
            {
              "symbol": "BRBR"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "INDV"
            },
            {
              "symbol": "PVLA"
            },
            {
              "symbol": "IT"
            },
            {
              "symbol": "XLO"
            },
            {
              "symbol": "KMPR"
            },
            {
              "symbol": "ALC"
            },
            {
              "symbol": "FOUR"
            },
            {
              "symbol": "FOUR-PA"
            },
            {
              "symbol": "LDOS"
            },
            {
              "symbol": "SNAP"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-06T12:45:00+00:00",
    "headline": "Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer",
    "summary": "Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the initiation of the Phase 1b t",
    "url": "https://finance.yahoo.com/news/actuate-therapeutics-collaborate-incyte-corporation-124500889.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "5ae8ea9a-bcf6-3ff2-b004-1f1e751a7ab8",
      "content": {
        "id": "5ae8ea9a-bcf6-3ff2-b004-1f1e751a7ab8",
        "contentType": "STORY",
        "title": "Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer",
        "description": "",
        "summary": "Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the initiation of the Phase 1b t",
        "pubDate": "2025-08-06T12:45:00Z",
        "displayTime": "2025-08-06T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/e95e69f988edfe7b7f06243be5d07dd2",
          "originalWidth": 4772,
          "originalHeight": 1864,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Cl2WY9yOdkOr6IrhgdKdew--~B/aD0xODY0O3c9NDc3MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e95e69f988edfe7b7f06243be5d07dd2.cf.webp",
              "width": 4772,
              "height": 1864,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7CdFNhZ9yLPmXlxKh7pfDw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e95e69f988edfe7b7f06243be5d07dd2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/actuate-therapeutics-collaborate-incyte-corporation-124500889.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/actuate-therapeutics-collaborate-incyte-corporation-124500889.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ACTU"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]